Search
Searching Content indexed under Life Sciences, Biotechnology & Nanotechnology by Seyfarth Shaw LLP ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
New Safety Hazards From Nanotechnology Materials And Processes On The Horizon
The Nanotechnology Research Center (NTRC), part of the National Institute for Occupational Safety and Health (NIOSH),
United States
29 Aug 2019
2
Future Enterprises: New Safety Hazards From Nanotechnology Materials And Processes On The Horizon
One of the potential safety issues facing employers relates to the use of nanomaterials and processes involving nanotechnology in the workplace.
United States
28 Aug 2019
3
Health Care Employers Face Workplace Safety Challenges From Virulent New Multidrug-Resistant Fungus
Health care providers are increasingly called upon to address drug resistant medical cases such as Candida auris.
United States
7 May 2019
4
Biosimilar IPRs: Timing Is Everything . . . But When Is The Right Time?
Timing the filing of an inter partes review for companies in the early stage of developing a biosimilar product should be carefully considered based on the recent Federal Circuit case,
United States
15 Mar 2019
5
The Internet Of Things + Medical Devices = Liability (Part 2)
In the first part of this post, we examined the security risks posed by the growing "Internet of Things," especially as connected implants and other medical devices become more common.
United States
27 Jun 2018
6
The Internet Of Things + Medical Devices = Liability (Part 1)
We all remember the video from a few years ago in which (benevolent) hackers remotely seized control of an SUV, initially playing with the climate control, stereo, and screen but then interfering...
United States
25 Jun 2018
7
Good ANDA Submission Practices: Summary Of Draft Guidance
The Food and Drug Administration (FDA), as part of its Drug Competition Action Plan, published a draft guidance detailing good practices for the submission of ANDAs on January 3, 2018.
United States
4 Apr 2018
8
No Longer The Stuff Of Science Fiction: The FDA's New Policy Approach To Regenerative Medicine Products
The ability to facilitate the regeneration of parts of the human body is "no longer the stuff of science fiction" according to FDA Commissioner Scott Gottlieb.
United States
13 Dec 2017
9
When Are Swashbuckling Experts Seemingly ‘Flooding' A Court With Large Number Of References?
In Bayer Pharma AG v. Watson Laboratories, Inc. (Fed. Cir. November 1, 2017), the Federal Circuit overturned the District of Delaware's finding that Watson failed ...
United States
17 Nov 2017
10
Sandoz V. Amgen: The Latest In Biosimilar Dances
Finding against the Federal Circuit once again on a patent case, the Supreme Court issued a unanimous decision in Sandoz v. Amgen relating to the interpretation of the Biologics Price Competition...
United States
24 Jul 2017
11
Sandoz V. Teva: Supreme Court Nixes Post-approval Waiting Period For Biosimilars
Finding against the Federal Circuit once again on a patent case, the Supreme Court this week issued a unanimous decision in Sandoz v. Amgen relating to the interpretation of the Biologics...
United States
23 Jun 2017
12
Legislative Overview: First Quarter 2017
One goal of BioLoquitur is to provide commentary and analysis on important developments in U.S. law affecting the pharmaceutical and biologics industry.
United States
28 Apr 2017
13
Introducing Seyfarth's BioLoquitur Blog
Seyfarth's Intellectual Property Practice Group is delighted to announce the launch of BioLoquitur on LexBlog.
United States
13 Apr 2017
Links to Result pages
 
1